Previous close | 50.75 |
Open | 50.87 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 50.87 - 50.87 |
52-week range | 38.16 - 70.50 |
Volume | |
Avg. volume | 2,718 |
Market cap | 13.881B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 30.50 |
EPS (TTM) | 1.67 |
Earnings date | N/A |
Forward dividend & yield | 0.88 (1.70%) |
Ex-dividend date | 03 Mar 2023 |
1y target est | N/A |
The proposed combination of Novozymes and Chr. Hansen has now been approved by each company’s respective shareholders, and with strong support from the shareholders the two biosolutions companies are now one step closer to uniting. The new company is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – March 30, 2023. Today, Novozymes and Chr. Hansen held their respective extraordinary gener
To the shareholders of NovozymesThe Board of Directors is pleased to invite you to an extraordinary shareholders’ meeting of Novozymes to be held on Thursday March 30, 2023 at 12:00 (noon) CEST at Ballerup Super Arena. Please read the invitation in PDF Til Novozymes’ aktionærerBestyrelsen har hermed fornøjelsen af at invitere til ekstraordinær generalforsamling i Novozymes torsdag den 30. marts 2023 kl. 12.00 i Ballerup Super Arena. Læs venligst den fulde invitation i PDF format Attachments Noti
WLKP vs. NVZMY: Which Stock Is the Better Value Option?